Skip to main content
. Author manuscript; available in PMC: 2013 Aug 5.
Published in final edited form as: Vaccine. 2011 Dec 4;30(5):922–930. doi: 10.1016/j.vaccine.2011.11.089

Fig. 5.

Fig. 5

Sera from animals immunized with hyperglycosylated mutant Q105N mixed with Quil A elicit greater CD4bs-directed responses. (A) All sera bind fairly equally to construct XOD6, indicating that all contain antibodies to the outer domain portion of gp120. (B) The Q105N_QuilA formulation elicited a significantly higher proportion of antibodies to epitopes overlapping the CD4bs relative to gp120wt mixed with the same adjuvant as judged by stronger affinity for the RSC3 mutant. **, p < 0.01; ***, p < 0.001. (C) None of the sera bound significantly less to mutant RSC3Δ371I compared to RSC3, suggesting that the elicited CD4bs-specific antibodies do not require Ile371 for binding. Error bars denote the signal ranges from replicate wells.